Ziopharm Oncology Reports First Quarter 2019 Financial Results and Reaffirms Clinical Timelines
- Phase 1 Trial of Sleeping Beauty TCR-T cell therapy for patients with solid tumors to begin at NCI in mid-2019 – - Third-generation Sleeping Beauty CD19-specific CAR-T U.S. trial to begin in 2H2019 – - Phase 2 trial of Controlled IL-12 in combination …